ArticleBlood advances2023

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nancy L Bartlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.